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Abstract 
A unified synthetic approach was developed that enabled the synthesis of diverse tropane-related scaffolds.  The 
key intermediates that were exploited were cycloadducts formed by reaction between 3-hydroxy-pyridinium salts 
and vinyl sulfones or sulfonamides.  The diverse tropane-related scaffolds were formed by addition of substituents 
to, cyclisation reactions of, and fusion of additional ring(s) to the key bicyclic intermediates.  A set of 53 screening 
compounds was designed, synthesised and evaluated in order to determine the biological relevance of the scaffolds 
accessible using the synthetic approach.  Two inhibitors of Hedgehog signalling, and four compounds with weak 
activity against the parasite P. falciparum, were discovered.  Three of the active compounds may be considered to 
be indotropane or pyrrotropane pseudo natural products in which a tropane is fused with a fragment from another 
natural product class.  It was concluded that the unified synthetic approach had yielded diverse scaffolds suitable 
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Introduction 
Natural products continue to provide rich inspiration in medicinal chemistry and chemical biology.  Natural 
products have played a crucial role in shaping early-stage drug discovery: 6% of the drugs approved for clinical use 
between 1981 and 2014 were unaltered natural products, and 26% were natural product derivatives.1  
Furthermore, in biology-oriented synthesis, natural product scaffolds are used to guide the design of productive 
screening libraries.2a  Screening libraries can provide useful starting points for the discovery of both drugs and 
chemical probes, and diversity-oriented synthetic approaches have been developed to increase both the chemical 
functional diversity that may be explored.2b-d 
The tropane alkaloids are structurally diverse, and display a broad range of biological functions (Figure 1).3  
Within this class of alkaloids, the [3.2.1]bicyclic  tropane core may be substituted at a wide range of positions (as in 
ecgonine and catuabine A), and can also be fused with additional rings (as in alstoniaphylline B and 2,3-
dihydrodarlingine).  The tropane core is also in clinically-approved drugs including maraviroc,4 an HIV-1 entry 
inhibitor, and atropine, a drug that used to treat bradycardia.  The tropane alkaloids have also provided wider 
inspiration in medicinal chemistry, for example in the discovery of dopamine reuptake inhibitors,5 muscarinic 
acetylcholine receptor antagonists6 and monoamine uptake inhibitors7 (e.g. 1).  Recently, tropanes have inspired 
the design of pseudo natural product scaffolds in which the bicyclic is fused with other natural product-inspired 
ring systems: for example indotropanes8 (fused with an indole) and pyrrotropanes9 (fused with a pyrrolidine).  The 





Figure 1: Examples of tropane alkaloids (top) and tropane-related compounds (bottom) 
 
We have developed a unified synthesis of diverse tropane-related scaffolds in which the bicyclic cycloadducts 
4 were exploited as key intermediates (Scheme 1).10  It was envisaged that the functionality in the cycloadducts 4 
would enable the addition of substituents to several positions of the tropane core (e.g. to give 5).  Furthermore, 
the synthesis of more complex tropane-related scaffolds would be possible, either by cyclisation of the cycloadducts 
4 (e.g. to give the scaffold 6) or by fusion of additional ring(s) (e.g. to give the scaffolds 7 or 8).  It was noted that 
some of the resulting structures may be considered to be pseudo natural product scaffolds in which the tropane 
core has been fused with other natural product fragments: for example indotropanes (e.g. 8), 
tetrahydroquinotropanes (e.g. 6) and pyrrotropanes (e.g. 7).  In this paper, we describe the development of the 
unified synthesis, and the design and synthesis of a set of diverse screening compounds based on many of the 
resulting scaffolds.  In addition, we demonstrated the biological relevance of some of the approach through the 





Scheme 1: Overview of the envisaged unified synthetic approach 
 
Results and Discussion 
Synthesis of bicyclic intermediates 
Initially, we investigated the synthesis of the key bicyclic intermediates (Scheme 2 and Table 1).  The 3-hydroxy-
pyridinium salts 10 were prepared in near-quantitative yield by alkylation of 3-hydroxy pyridine, and were used 
without further purification.  The 3-hydroxy pyridinium salts 10 and appropriate dipolarophiles were treated with 
triethylamine, and the corresponding cycloadducts were obtained after reaction at elevated temperature.11  The 
reactions proceeded with high regio- and stereoselectivity with a vinyl sulfone or a vinyl sulfonamide as 
dipolarophile; in contrast, our and other11 studies showed that the cycloaddition reactions were poorly selective 
with acrylonitrile or acrylate esters as the dipolarophile.  The stereochemical outcome of the cycloadditions was 
consistent with previous studies,11 and the relative configurations of derivatives of 11b, 11c and 11f were 
determined by X-ray crystallography (vide infra).  Although the yields of the cycloadducts were generally good, 
lower yields were often obtained with the methylated 3-hydroxy pyridinium salt 10b which was, nevertheless, 
consumed during the reactions.  It was hypothesised that the iodide counterion dealkylated 10b under the reaction 
conditions and, indeed, the yield of 11c was improved from 20% to 67% when Ag2O was used as a base that could 





Scheme 2: Synthesis of bicyclic intermediates (see Table 1) 
 
Table 1: Synthesis of bicyclic intermediates (see Scheme 2) 
3-Hydroxy pyridinium salt formation Bicyclic intermediate formation 
R X Solvent Product  
(Yield) 
R R’ Product 
(Yield) 
Bn Br iPrOH 10a (99%) Bn Ph 11a (70%) 
Bn Me 11b (57%) 
Me I iPrOH 10b (99%) Me Me 11c (67%)a 
Me NMe2 11d (54%) 
Me Ph 11e (20%) 
p-FC6H4CH2- Br THF 10c (99%) p-FC6H4CH2- Me 11f (50%) 
o-BrC6H4CH2- Br THF 10d (99%) o-BrC6H4CH2- Ph 11g (41%) 
o-Br-p-FC6H3CH2- Br THF 10e (99%) o-Br-p-FC6H3CH2- Me 11h (89%) 
aAg2O was used as base; 20% yield with Et3N as base. 
 
Functional group manipulation of the bicyclic scaffolds 11 was undertaken to enable subsequent scaffold 
syntheses (Scheme 3).  For example, hydrogenation of the enones 11 proceeded in high yield to give the 
corresponding bicyclic saturated ketones 12.  Furthermore, reduction of 12a with iBu2AlH gave the corresponding 
alcohol with >98:<2 diastereoselectivity.  After TBS protection, the resulting sulfone was treated with LiHMDS and 
then MeSSMe; subsequent treatment with HCl resulted in hydrolysis of both the -methylsulfanyl sulfone and the 





Scheme 3: Functional group manipulation of bicyclic intermediates 
 
Synthesis of diverse tropane-related scaffolds 
A wide range of scaffolds was prepared in which additional ring(s) were fused onto the tropane core (Scheme 
4).  Treatment of the enone 11a with toluenesulfonylmethyl isocyanide13 and potassium tert-butoxide gave the 
corresponding pyrrole 14 in 85% yield.  Highly diastereoselective fusion of an N-benzyl pyrrolidine ring14 was 
possible by treatment of enones 11b, 11c, 11e and 11f with Me3SiCH2NBnCH2OMe and lithium fluoride in 
acetonitrile at room temperature (→ 7a-d, see legend for details).14a  The relative configuration of a derivative of 
7d was determined by X-ray crystallography (vide infra).  Alternatively, reaction of the enone 11a with N-methyl 
glycine and paraformaldehyde14b in refluxing toluene resulted in fusion of an N-methyl pyrrolidine ring to give 7e in 
77% yield and with high diastereoselectivity.  The cyclopropane 15 was prepared in good yield and with >98:<2 
diastereoselectivity by treatment of 11a with dimethyloxosulfonium methylide; the configuration of 15 was 
determined by correlation with predicted coupling constants for the alternative diastereomers (Supporting 
Information).15  Treatment of the enone 11b with ethyl diazoacetate,16 followed by hydrolysis with aqueous sodium 
hydroxide, gave, presumably after aerobic oxidation, the pyrazole 16 in low yield.  Finally, reaction of the enone 




Scheme 4: Scaffold synthesis by ring fusion onto bicyclic intermediates.  Conditions: (a) TsCH2NC, tBuOK, THF, 0 ºC 
→ rt, 85%; (b) Me3SiCH2NBnCH2OMe, LiF, MeCN: 7a (R=Me, R’=Ph, R’’=Bn), 67% (from 11e); 7b (R=Me, R’=Me, 
R’’=Bn), 50% (from 11c); 7c (R=Bn, R’=Me, R’’=Bn), 57% (from 11b); 7d (R=p-FC6H4CH2-, R’=Me, R’’=Bn), 88% (from 
11f); (c) MeNHCH2CO2H, paraformaldehyde, toluene, : 7e (R=Bn, R’=Ph, R’’=Me), 77% (from 11a); (d) Me3SO I, 
NaH, THF, 40%; (e) ethyl diazoacetate, THF then NaOH, H2OMeOH, 14%; (f) EtNO2, PhNCO, THFEt2O, 28% then 
DDQ, toluene, , 16%; (g) 2,4,6-tri(trifluoromethyl)-1,3,5-triazine, 10 mol% TFA, EtOH, 80 ºC: 18a (R=Bn), 32% (from 
12b); 18b (R=Me), 54% (from 12c); (h) NCS, 30 mol% proline, CH2Cl2 then R’’CSNH2, DMF: 19a (R’=R’’=Me), 3% over 
2 steps (from 12b); 19b (R’=R’’=Ph), 30% over 2 steps (from 12a); (i) R’CCCH2NH2, 2.5 mol% NaAuCl4•2H2O, EtOH, 
80 ºC: 20a (R=Bn, R’=Me, R’’=H), 63% (from 12b); 20b (R=Me, R’=Me, R’’=H), 43% (from 12b); 20c (R=Me, R’=NMe2, 
R’’=H), 40% (from 12d); 20d (R=Me, R’=Me, R’’=Ph), 20% (from 12c); (j) o-IC6H4NH2, 10 mol% Pd(OAc)2, DABCO, 
DMF: 8a (R=Bn, R’=Ph), 40% (from 12a); 8b (R=Me, R’=NMe2), 29% (from 12d); 8c (R=Bn, R’=Me), 20% (from 12b); 
8d (R=Me, R’=Me), 17% (from 12c); (k) PhNHNH2, AcOH, : 8a (R=Bn, R’=Ph), 40% (from 12a). 
 
The position of ring fusion to the tropane core could be varied by exploiting the saturated ketones 12 in place 
of the enones 11 (Scheme 4).  Accordingly, treatment of 12b and 12c  with 2,4,6-tri(trifluoromethyl)-1,3,5-triazine18 
and 10 mol% trifluoroacetic acid in refluxing ethanol gave the pyrimidines 18a and 18b in 32% and 54% yield 
respectively.  Alternatively, -chlorination of the ketones 12a and 12b,19 followed by reaction with thioacetamide 
or thiobenzamide,20 gave the thiazoles 19.  Fusion of a pyridine ring was possible by treatment of the ketones 12 
and an appropriate propargylamine with 2.5 mol% NaAuCl4 (→ 20).21  Finally, either Fischer indole synthesis22 or 





Scheme 5: Scaffold synthesis by cyclisation of bicyclic intermediates. 
 
Two complementary cyclisation reactions enabled conversion of the enones 11 into more complex scaffolds 
(Scheme 5).  Treatment of 11a with MeLi resulted in deprotonation and cyclisation, rather then methyl addition to 
the ketone, to give the cyclopropane 21 in 20% yield; the yield of the process was improved to 60% with LiHMDS 
as base in place of MeLi.  Finally, reductive Heck cyclisation24 between the aryl bromide and the enone of 11g and 
11h gave the tetrahydroquinotropanes 6a and 6b. 
Substitution of the enones 11 was possible at alternative positions (Scheme 6).  Rh-catalysed conjugate 
addition25 of aryl-boronic acids to the enones 11b and 11c yielded the corresponding aryl-substituted tropanes 22a-
e with high diastereoselectivity.  The relative configuration of derivatives of 22c and 22d was determined by X-ray 
crystallography (vide infra).  In addition, a Bayliss-Hillman reaction of the enone 11a yielded the hydroxymethyl-
substituted enone 23. 
 
Scheme 6: Exploration of alternative vectors by functionalisation of bicyclic intermediates 
 
The unified approach had enabled the synthesis of sixteen distinct deprotected graph-node-bond level26 
scaffolds in which alpha atoms had been removed.  The diversity of these scaffolds may be captured in terms of an 
hierarchical tree27 that formalises the relationship between molecular scaffolds (Figure 2).  We used the open 
access-computional tool LLAMA28 to assess the novelty of the scaffolds with respect to a random 2% of the ZINC 
database of commercially-available compounds.29  Only two of the 16 final scaffolds were found as substructures 




Figure 2: Hierarchical relationship between the tropane-related scaffolds.  Scaffolds that were found as 
substructrues of a random 2% of the ZINC database of commercially-available compounds are noted. 
 
Design, synthesis and evaluation of a small molecule library based on diverse tropane-related scaffolds 
A range of building blocks was prepared in which the protecting groups were chosen to enable decoration of 
the scaffolds at complementary positions (Scheme 7).  Hydrogenation of the enone 11b under forcing conditions in 
methanolacetone resulted in debenzylation, alkene and ketone reduction and iso-propylation (by reaction with 
acetone) to give the hydroxyl-substituted tropane 24.  Reductive amination of the ketone 12c, by treatment with 
methylamine, Ti(OiPr)4 and then sodium borohydride gave the secondary amine 25 in 41% and with high 
diastereoselectivity; the relative configuration of similar reductive amination products was determined by NOESY 
analysis (Supplementary Information).  In a similar vein, reaction of the ketones 22c, 22d and 7d with iBu2AlH was 
moderately diastereoselective (crude dr observed with these substrates: 22c, 75:25; 22d, 90:10; 7d, 75:25) and, 
after purification, yielded the corresponding alcohols 27a, 27b and 28 as single diastereomers.  Finally, 
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hydrogenolysis of 22a, 27b and 28 yielded the corresponding debenzylated building blocks 26, 27c and 29.  The 
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Figure 3: Construction of a set of 53 screening compounds.  Panel A: Exemplar screening compounds (see Table 2 
for synthesis and Supplementary Information).  Panels B and C:  Molecular properties (B) and shape diversity  (C) 
of the library (see Supplementary Information).  Shape diversity is represented on a principal moments of inertia 
(PMI) plot in which the vertices correspond to linear (top left), flat (bottom) and spherical (top right) shapes. 
 
A set of 53 screening compounds based on many of the tropane-related scaffolds was designed and prepared.  
In addition to compounds that had already been prepared (6a, 6b, 8b, 8c, 8d, 12c, 13, 14, 16, 17, 18a, 18b, 19a, 
19b, 20a, 20b, 20c, 20d, 22e, 24, 25, 27a, 27c and 29), additional compounds were also synthesised by derivatisation 
of building blocks (see Scheme 7) with a single capping group.  Final compounds were generally purified by mass-
directed HPLC or automated reverse-phase flash column chromatography; purification was often challenging, and 
low yield of purified products were often obtained using these methods.  The synthesis of ten exemplar screening 
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compounds (see Figure 3, Panel A) is summarised in Table 2 (see also Supplementary Information).  The molecular 
properties (Panel B) and shape diversity (Panel C) of the screening compounds is summarised in Figure 3.  The 
screening compounds generally have drug-like molecular properties, and are more three-dimensional than many 
screening sets.31 
 
Table 2: Synthesis of exemplar screening compounds 
Substrate Method Product 
(Yield) 
27c 4-bromomethyl-benzonitrile, NaH, DMF 30 (12a) 
27c cPrCOCl, pyridine, CH2Cl2 31 (16a) 
27c 1-methylimidazole-2-sulfonyl chloride, pyridine, DMF 32 (4a) 
29 isonicotinaldehyde, DMF then NaBH4 33 (41b) 
24 4-methoxyphenylisocyanate, NaH, DMF 34 (10b) 
24 2-chlorobenzoxazole, NaH, DMF 35 (7b) 
25 1-methylimidazole-2-sulfonyl chloride, pyridine, DMF 36 (21b) 
25 3-isocyanatobenzonitrile, NaHCO3, DMF 37 (35b) 
8c MsCl, NaH, DMF 38 (11b) 
8c BrCH2CN, NaH, DMF 39 (19b) 
aPurification by mass-directed HPLC.  bPurification by automated reverse-phase flash column chromatography. 
 
The 53 final compounds were screened in two phenotypic assays that were selected as representative 
applications of the library.  It was intended that these assays would enable a preliminary assessment of the 
biological relevance of the scaffolds accessible using the unified synthetic approach.  An osteoblast differentiation 
assay32 was used to screen the compounds, initially at 10 M, for inhibition of Hedgehog signalling.  The dose-
dependent activity of hits, identified on the basis of at least 50% inhibition of signallig and <20% impact on cell 
viability, was determined.  In addition, a screen against a NF54 (chloroquine-susceptible) P. falciparum strain was 
performed in dose-response mode in which lactate dehydrogenase activity served as a marker for parasite 
viability.33  The dose-dependent activity of the active compounds from both assays is shown in Figure 4.  Two 
inhibitors of Hedgehog signalling were discovered (38 and 39; Panel A), both of which were based on a tetracyclic 
indotropane scaffold that is a substructure of some known8b inhibitors of this pathway (such as 3, Figure 1).  Four 
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compounds with weak antiplasmodium activity were also identified (16, 20, 40 and 41; Panel B); these compounds 
were based on four distinct tropane-related scaffolds that had been prepared.  We note that three of the active 
compounds may be considered to be pseudo natural products in which a tropane is fused with a fragment from 
another natural product class: 38 and 39 are indotropanes and 41 is a pyrrolotropane.9 
 
 
Figure 4: Structures of bioactive ligands discovered.  Panel A: Inhibitors of Hedgehog signalling.  Panel B: Inhibitors 
of P. falciparum survival.  Compound 41 was tested as a 85:15 mixture of diastereomers. 
 
Conclusion 
A unified synthetic approach was developed that enabled the synthesis of diverse tropane-related scaffolds.  
The bicyclic cycloadducts 11 were exploited as key intermediates which were converted into diverse scaffolds by 
the addition of substituents, cyclisation reactions, and the fusion of additional ring(s).  In total, the approach 
enabled the synthesis of sixteen distinct scaffolds, only two of which were found in a substructure search of 
commercially-available compounds.  The biological relevance of the scaffolds that were accessible using the 
approach was determined by design, synthesis and evaluation of 53 screening compounds.  The set of screening 
compounds was screened, enabling discovery of two inhibitors of Hedgehog signalling and four compounds with 
activity against P. falciparum.  Three of these compounds may be considered to be indotropane or pyrrotropane 
pseudo natural products in which a tropane is fused with a fragment from another natural product class.  We 
14 
 
conclude that unified approaches for the synthesis of diverse natural product-inspired scaffolds can underpin the 
design of performance-diverse screening libraries. 
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